Bio News

U.S.-based McKesson will acquire Precision Medicine Group for $2.25 billion (approximately 3.17 trillion won). Precision Medicine Group provides oncology clinical services, including clinical trial design and biomarker identification. After regulatory review is completed, McKesson will integrate Precision Medicine Group into its oncology and complex-care division.

Biobook Team
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882